Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

OMNARIS

CICLESONIDE

Standard Dose
50MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OMNARIS is listed in Drugs@FDA under application 022124 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength SPRAY; NASAL - 50MCG Sponsor NYCOMED US INC Submission history Latest submission status date: 2007-11-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview OMNARIS is listed in Drugs@FDA under application 022124 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CICLESONIDE Form and strength SPRAY; NASAL - 50MCG Sponsor NYCOMED US INC Submission history Latest submission status date: 2007-11-21 00:00:00. Submission type: ORIG.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.